

Freedom of Information Request	FOI 21-018	2 <sup>nd</sup> February 2021
--------------------------------	------------	-------------------------------

**Q1. How many patients have been treated (for any disease) in the last three months with:**

- **Benralizumab**
- **Omalizumab**
- **Reslizumab**
- **Mepolizumab**

APPROVED NAME	DOSE FORM	STRENGTH	UNIT OF ISSUE	*QUANTITY ISSUED
OMALIZUMAB	INJECTION	150mg	1 PRE-FILLED SYRINGE	807
OMALIZUMAB	INJECTION	75mg	1 PRE-FILLED SYRINGE	48
MEPOLIZUMAB		100mg	1 SC INJECTION	115
MEPOLIZUMAB		100mg	1 PREFILLED PEN	41
BENRALIZUMAB	SUB-CUTANEOUS INJECTION	30mg in 1ml	1 PRE-FILLED SYRINGE	3
BENRALIZUMAB	SUB-CUTANEOUS INJECTION	30mg in 1ml	1 X 1ml PEN	5

\* The Health Board is unable to provide data by patient so have included quantities dispensed

**Q2. How many patients have been treated in the last three months, for asthma ONLY, with:**

- **Dupilumab**
- **Upadacitinib**

No quantities issued were recorded on our system for this period.

**Q3. How many patients have been treated (with any medication) for severe asthma in the last three months? Of these patients, how many were children?**

The Health Board does not hold this information.